within Pharmacolibrary.Drugs.D_Dermatologicals.D03A_Cicatrizants.D03AX10_Enoxolone;

model Enoxolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 3.333333333333333e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0033333333333333335,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Enoxolone</td></tr><tr><td>ATC code:</td><td>D03AX10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Enoxolone, also known as glycyrrhetinic acid, is a pentacyclic triterpenoid derivative produced from the hydrolysis of glycyrrhizic acid from licorice root (Glycyrrhiza glabra). It has anti-inflammatory and anti-ulcerative properties and is used topically for skin conditions, and orally as an adjunct in the treatment of peptic ulcers, though its use is now rare due to side effects, such as mineralocorticoid excess.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a healthy adult population based on available data for glycyrrhetinic acid derivatives. No direct clinical pharmacokinetic studies reporting all parameter values found for enoxolone.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D03AX10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Enoxolone;
